BioCentury
ARTICLE | Company News

DFB, CritiTech, U.S. Biotest form NanOlogy

September 22, 2017 8:20 PM UTC

DFB Pharmaceuticals LLC (Fort Worth, Texas), CritiTech Inc. (Lawrence, Kan.) and U.S. Biotest Inc. (San Luis Obispo, Calif.) formed NanOlogy LLC (Fort Worth, Texas) to develop nanoparticle drug-delivery technology to treat cancer.

The newco's pipeline includes NanoPac, a nanoparticle form of paclitaxel, in Phase II testing to treat ovarian, prostate and pancreatic cancer as well as mucinous cystic pancreatic neoplasms. Data from the prostate and two pancreatic trials are expected next year. Data are also expected early next year from a Phase II trial of SOR007, a topical ointment of uncoated nanoparticle paclitaxel, to treat actinic keratosis lesions. A Phase II study of SOR007 to treat cutaneous metastases from non-melanoma cancer is expected to begin next quarter. DFB's affiliate DFB Soria LLC granted NanOlogy rights to SOR007 for cancer indications...